Updated American Society of Clinical Oncology guidelines indicate that Agendia's MammaPrint 70-gene lab test can guide decision-making for treating women with estrogen receptor-positive or progesterone receptor-positive, HER2-negative breast cancer with lymph node-negative, or up to three positive lymph nodes, who face a high clinical recurrence risk. The recommendation was backed by a 6,693-patient trial that showed the assay could identify patients with high clinical risk but low genomic risk who had a favorable outcome when treated with endocrine therapy alone, leading to a five-year distant metastasis-free survival rate comparable to chemotherapy.
ASCO guidelines recommend Agendia's MammaPrint test
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.